Cargando…

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer

BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalska, Aldona, Pałyga, Iwona, Gąsior-Perczak, Danuta, Walczyk, Agnieszka, Trybek, Tomasz, Słuszniak, Anna, Mężyk, Ryszard, Góźdź, Stanisław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521804/
https://www.ncbi.nlm.nih.gov/pubmed/26230494
http://dx.doi.org/10.1371/journal.pone.0133852
_version_ 1782383859697975296
author Kowalska, Aldona
Pałyga, Iwona
Gąsior-Perczak, Danuta
Walczyk, Agnieszka
Trybek, Tomasz
Słuszniak, Anna
Mężyk, Ryszard
Góźdź, Stanisław
author_facet Kowalska, Aldona
Pałyga, Iwona
Gąsior-Perczak, Danuta
Walczyk, Agnieszka
Trybek, Tomasz
Słuszniak, Anna
Mężyk, Ryszard
Góźdź, Stanisław
author_sort Kowalska, Aldona
collection PubMed
description BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated thyroglobulin (Tg) which, together with neck ultrasound (US), enables correct diagnosis in nearly all cases of the active disease. For many years the only known stimulation was a 4–5 week withdrawal from the L-T4 therapy (THW). For the last couple of years stimulation with the use of recombinant human TSH (rhTSH) has been available. This method of stimulation may have a significant influence in obtaining the Tg level. However, it is important to determine the cut-off level for rhTSH-stimulated Tg (rhTSH/Tg). MATERIALS AND METHODS: This is a retrospective analysis of consecutive patients from one facility who have qualified over a period of two years for repeated radioiodine therapy (RIA). In our facility the ablation effectiveness evaluation is always carried out with the use of rhTSH, with the repeated therapy following THW. Such a procedure enables two Tg measurements in the same patient after both types of stimulation within 4–5 weeks. The obtained values were compared, cut-off levels in THW conditions were used (2.0 ng/ml for patients in remission and 10.0 ng/ml for patients with an active disease). In order to determine the cut-off level for rhTSH/Tg, regression analysis and ROC curves were used. RESULTS: In 63 patients the Tg measurement of both methods of stimulation were obtained. It was observed that there was a high correlation between rhTSH/Tg and THW/Tg. However, the rhTSH/Tg level was significantly lower than THW/ Tg. The rhTSH/ Tg cut-off levels which corresponded to the 2.0 ng/ml and 10.0 ng/ml limits for THW/Tg were calculated and the values were 0.6 ng/ml and 2.3 ng/ml respectively. CONCLUSIONS: The method of stimulation has a significant impact on the obtained Tg concentrations. The assumed THW/Tg cut off levels must not be transferred to rhTSH/Tg.
format Online
Article
Text
id pubmed-4521804
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45218042015-08-06 The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer Kowalska, Aldona Pałyga, Iwona Gąsior-Perczak, Danuta Walczyk, Agnieszka Trybek, Tomasz Słuszniak, Anna Mężyk, Ryszard Góźdź, Stanisław PLoS One Research Article BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated thyroglobulin (Tg) which, together with neck ultrasound (US), enables correct diagnosis in nearly all cases of the active disease. For many years the only known stimulation was a 4–5 week withdrawal from the L-T4 therapy (THW). For the last couple of years stimulation with the use of recombinant human TSH (rhTSH) has been available. This method of stimulation may have a significant influence in obtaining the Tg level. However, it is important to determine the cut-off level for rhTSH-stimulated Tg (rhTSH/Tg). MATERIALS AND METHODS: This is a retrospective analysis of consecutive patients from one facility who have qualified over a period of two years for repeated radioiodine therapy (RIA). In our facility the ablation effectiveness evaluation is always carried out with the use of rhTSH, with the repeated therapy following THW. Such a procedure enables two Tg measurements in the same patient after both types of stimulation within 4–5 weeks. The obtained values were compared, cut-off levels in THW conditions were used (2.0 ng/ml for patients in remission and 10.0 ng/ml for patients with an active disease). In order to determine the cut-off level for rhTSH/Tg, regression analysis and ROC curves were used. RESULTS: In 63 patients the Tg measurement of both methods of stimulation were obtained. It was observed that there was a high correlation between rhTSH/Tg and THW/Tg. However, the rhTSH/Tg level was significantly lower than THW/ Tg. The rhTSH/ Tg cut-off levels which corresponded to the 2.0 ng/ml and 10.0 ng/ml limits for THW/Tg were calculated and the values were 0.6 ng/ml and 2.3 ng/ml respectively. CONCLUSIONS: The method of stimulation has a significant impact on the obtained Tg concentrations. The assumed THW/Tg cut off levels must not be transferred to rhTSH/Tg. Public Library of Science 2015-07-31 /pmc/articles/PMC4521804/ /pubmed/26230494 http://dx.doi.org/10.1371/journal.pone.0133852 Text en © 2015 Kowalska et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kowalska, Aldona
Pałyga, Iwona
Gąsior-Perczak, Danuta
Walczyk, Agnieszka
Trybek, Tomasz
Słuszniak, Anna
Mężyk, Ryszard
Góźdź, Stanisław
The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title_full The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title_fullStr The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title_full_unstemmed The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title_short The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
title_sort cut-off level of recombinant human tsh-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521804/
https://www.ncbi.nlm.nih.gov/pubmed/26230494
http://dx.doi.org/10.1371/journal.pone.0133852
work_keys_str_mv AT kowalskaaldona thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT pałygaiwona thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT gasiorperczakdanuta thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT walczykagnieszka thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT trybektomasz thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT słuszniakanna thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT mezykryszard thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT gozdzstanisław thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT kowalskaaldona cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT pałygaiwona cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT gasiorperczakdanuta cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT walczykagnieszka cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT trybektomasz cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT słuszniakanna cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT mezykryszard cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer
AT gozdzstanisław cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer